Kamada (KMDA) Retained Earnings (2012 - 2026)

Kamada (KMDA) posted quarterly Retained Earnings of -$27.4 million for Q1 2026, up 17.85% year-on-year from -$23.2 million in Q1 2025, and down 60.26% on a QoQ basis from -$17.1 million in Q4 2025.

Kamada (KMDA) Retained Earnings (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Retained Earnings for 15 consecutive years, with -$27.4 million the latest figure, recorded in Q1 2026.

  • Quarterly Retained Earnings rose 17.85% year-over-year to -$27.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.4 million (up 17.85% YoY) and the FY2025 annual result came in at -$17.1 million, up 33.66% from the prior year.
  • Retained Earnings eased to -$27.4 million in Q1 2026 per KMDA's latest filing, from -$17.1 million in the prior quarter.
  • Over the last five years, Retained Earnings for KMDA reached as high as -$50293.0 in Q1 2023 and fell as low as -$51.9 million in Q2 2022.
  • A 5-year average of -$31.4 million and a median of -$33.3 million in 2025 frame the typical range for Retained Earnings.
  • The largest YoY upside for Retained Earnings was 99.9% in 2023 against a maximum downside of 87902.64% in 2023.
  • Year by year, Retained Earnings stood at -$48.5 million in 2022, then grew by 17.09% to -$40.2 million in 2023, then surged by 35.98% to -$25.7 million in 2024, then jumped by 33.66% to -$17.1 million in 2025, then slumped by 60.26% to -$27.4 million in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods registered -$27.4 million, -$17.1 million, and -$20.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 37.04 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 28.20 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 1.11 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 4.54 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 8.83 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -1.81 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 18.66 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 589.60 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -2.13 Bn
10 Kamada 401.22 Mn 328.07 Mn 19.12 Mn -27.36 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -27.36 Mn
Dec 31, 2025 -17.07 Mn
Sep 30, 2025 -20.64 Mn
Jun 30, 2025 -25.93 Mn
Mar 31, 2025 -33.31 Mn
Dec 31, 2024 -25.74 Mn
Sep 30, 2024 -29.55 Mn
Jun 30, 2024 -33.41 Mn
Mar 31, 2024 -37.84 Mn
Dec 31, 2023 -40.20 Mn
Sep 30, 2023 -45.26 Mn
Jun 30, 2023 -48.48 Mn
Mar 31, 2023 -50,293.00
Dec 31, 2022 -48.48 Mn
Sep 30, 2022 -51,428.00
Jun 30, 2022 -51.91 Mn
Mar 31, 2022 -47.99 Mn
Dec 31, 2021 -46.16 Mn
Sep 30, 2021 -41.15 Mn
Jun 30, 2021 -40.31 Mn